Does the media favor ARQT or AXSM?

In the previous week, Axsome Therapeutics had 10 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 14 mentions for Axsome Therapeutics and 4 mentions for Arcutis Biotherapeutics. Arcutis Biotherapeutics' average media sentiment score of 0.85 beat Axsome Therapeutics' score of 0.61 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcutis Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Axsome Therapeutics 3 Very Positive mention(s) 5 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SMMT or ARQT?

In the previous week, Summit Therapeutics had 1 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 5 mentions for Summit Therapeutics and 4 mentions for Arcutis Biotherapeutics. Arcutis Biotherapeutics' average media sentiment score of 0.85 beat Summit Therapeutics' score of 0.42 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arcutis Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ELAN or ARQT?

In the previous week, Elanco Animal Health had 3 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 7 mentions for Elanco Animal Health and 4 mentions for Arcutis Biotherapeutics. Elanco Animal Health's average media sentiment score of 1.31 beat Arcutis Biotherapeutics' score of 0.85 indicating that Elanco Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcutis Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ARQT or ARWR?

In the previous week, Arrowhead Pharmaceuticals had 8 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 12 mentions for Arrowhead Pharmaceuticals and 4 mentions for Arcutis Biotherapeutics. Arcutis Biotherapeutics' average media sentiment score of 0.85 beat Arrowhead Pharmaceuticals' score of 0.73 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcutis Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arrowhead Pharmaceuticals 4 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer RDY or ARQT?

Arcutis Biotherapeutics has a consensus target price of $34.00, indicating a potential upside of 19.34%. Given Arcutis Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Arcutis Biotherapeutics is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Reddy's Laboratories 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Arcutis Biotherapeutics 1 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.50

Does the media refer more to RDY or ARQT?

In the previous week, Dr. Reddy's Laboratories and Dr. Reddy's Laboratories both had 4 articles in the media. Arcutis Biotherapeutics' average media sentiment score of 0.85 beat Dr. Reddy's Laboratories' score of 0.42 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dr. Reddy's Laboratories 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arcutis Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Arcutis Biotherapeutics (ARQT) Competitors

$28.49 +0.75 (+2.70%)

Closing price 07/17/2026 04:00 PM Eastern

Extended Trading

$28.15 -0.34 (-1.19%)

As of 07/17/2026 05:39 PM Eastern

Compare

ARQT vs. AXSM, SMMT, ELAN, ARWR, and RDY

Should you buy Arcutis Biotherapeutics stock or one of its competitors? MarketBeat compares Arcutis Biotherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Arcutis Biotherapeutics include Axsome Therapeutics (AXSM), Summit Therapeutics (SMMT), Elanco Animal Health (ELAN), Arrowhead Pharmaceuticals (ARWR), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical products" industry.

How does Arcutis Biotherapeutics compare to Axsome Therapeutics?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and earnings.

81.5% of Axsome Therapeutics shares are held by institutional investors. 9.4% of Arcutis Biotherapeutics shares are held by company insiders. Comparatively, 20.6% of Axsome Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Arcutis Biotherapeutics has a beta of 1.48, suggesting that its share price is 48% more volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.6, suggesting that its share price is 40% less volatile than the broader market.

Arcutis Biotherapeutics presently has a consensus price target of $34.00, indicating a potential upside of 19.34%. Axsome Therapeutics has a consensus price target of $259.05, indicating a potential upside of 12.63%. Given Arcutis Biotherapeutics' higher probable upside, analysts plainly believe Arcutis Biotherapeutics is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Axsome Therapeutics	1 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.95

In the previous week, Axsome Therapeutics had 10 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 14 mentions for Axsome Therapeutics and 4 mentions for Arcutis Biotherapeutics. Arcutis Biotherapeutics' average media sentiment score of 0.85 beat Axsome Therapeutics' score of 0.61 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcutis Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Axsome Therapeutics	3 Very Positive mention(s)	5 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arcutis Biotherapeutics has higher earnings, but lower revenue than Axsome Therapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Axsome Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$415.62M	8.57	-$16.14M	-$0.03	N/A
Axsome Therapeutics	$638.50M	18.54	-$183.17M	-$3.73	N/A

Arcutis Biotherapeutics has a net margin of -0.57% compared to Axsome Therapeutics' net margin of -26.59%. Arcutis Biotherapeutics' return on equity of -1.41% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	-0.57%	-1.41%	-0.59%
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

Summary

Axsome Therapeutics beats Arcutis Biotherapeutics on 9 of the 17 factors compared between the two stocks.

How does Arcutis Biotherapeutics compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

In the previous week, Summit Therapeutics had 1 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 5 mentions for Summit Therapeutics and 4 mentions for Arcutis Biotherapeutics. Arcutis Biotherapeutics' average media sentiment score of 0.85 beat Summit Therapeutics' score of 0.42 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arcutis Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summit Therapeutics has a beta of -1.26, indicating that its stock price is 226% less volatile than the broader market. Comparatively, Arcutis Biotherapeutics has a beta of 1.48, indicating that its stock price is 48% more volatile than the broader market.

Summit Therapeutics currently has a consensus target price of $26.97, indicating a potential upside of 95.31%. Arcutis Biotherapeutics has a consensus target price of $34.00, indicating a potential upside of 19.34%. Given Summit Therapeutics' higher probable upside, equities research analysts clearly believe Summit Therapeutics is more favorable than Arcutis Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	2 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.44
Arcutis Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Arcutis Biotherapeutics has higher revenue and earnings than Summit Therapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A
Arcutis Biotherapeutics	$415.62M	8.57	-$16.14M	-$0.03	N/A

Summit Therapeutics has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -0.57%. Arcutis Biotherapeutics' return on equity of -1.41% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-291.24%	-243.07%
Arcutis Biotherapeutics	-0.57%	-1.41%	-0.59%

4.6% of Summit Therapeutics shares are owned by institutional investors. 83.5% of Summit Therapeutics shares are owned by insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Summit Therapeutics and Arcutis Biotherapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Arcutis Biotherapeutics compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings and analyst recommendations.

Arcutis Biotherapeutics has lower revenue, but higher earnings than Elanco Animal Health. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.89B	2.64	-$232M	-$0.50	N/A
Arcutis Biotherapeutics	$415.62M	8.57	-$16.14M	-$0.03	N/A

In the previous week, Elanco Animal Health had 3 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 7 mentions for Elanco Animal Health and 4 mentions for Arcutis Biotherapeutics. Elanco Animal Health's average media sentiment score of 1.31 beat Arcutis Biotherapeutics' score of 0.85 indicating that Elanco Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcutis Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Elanco Animal Health presently has a consensus price target of $28.55, suggesting a potential upside of 10.47%. Arcutis Biotherapeutics has a consensus price target of $34.00, suggesting a potential upside of 19.34%. Given Arcutis Biotherapeutics' higher probable upside, analysts plainly believe Arcutis Biotherapeutics is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Arcutis Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Elanco Animal Health has a beta of 1.68, meaning that its stock price is 68% more volatile than the broader market. Comparatively, Arcutis Biotherapeutics has a beta of 1.48, meaning that its stock price is 48% more volatile than the broader market.

Arcutis Biotherapeutics has a net margin of -0.57% compared to Elanco Animal Health's net margin of -4.95%. Elanco Animal Health's return on equity of 7.42% beat Arcutis Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-4.95%	7.42%	3.66%
Arcutis Biotherapeutics	-0.57%	-1.41%	-0.59%

97.5% of Elanco Animal Health shares are owned by institutional investors. 1.1% of Elanco Animal Health shares are owned by company insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Elanco Animal Health beats Arcutis Biotherapeutics on 11 of the 17 factors compared between the two stocks.

How does Arcutis Biotherapeutics compare to Arrowhead Pharmaceuticals?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

Arcutis Biotherapeutics currently has a consensus price target of $34.00, suggesting a potential upside of 19.34%. Arrowhead Pharmaceuticals has a consensus price target of $88.75, suggesting a potential upside of 19.45%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Arrowhead Pharmaceuticals is more favorable than Arcutis Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71

In the previous week, Arrowhead Pharmaceuticals had 8 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 12 mentions for Arrowhead Pharmaceuticals and 4 mentions for Arcutis Biotherapeutics. Arcutis Biotherapeutics' average media sentiment score of 0.85 beat Arrowhead Pharmaceuticals' score of 0.73 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcutis Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arrowhead Pharmaceuticals	4 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arcutis Biotherapeutics has a beta of 1.48, indicating that its share price is 48% more volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market.

Arrowhead Pharmaceuticals has higher revenue and earnings than Arcutis Biotherapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Arrowhead Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$415.62M	8.57	-$16.14M	-$0.03	N/A
Arrowhead Pharmaceuticals	$622.01M	16.83	-$1.63M	-$2.15	N/A

Arcutis Biotherapeutics has a net margin of -0.57% compared to Arrowhead Pharmaceuticals' net margin of -48.38%. Arcutis Biotherapeutics' return on equity of -1.41% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	-0.57%	-1.41%	-0.59%
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%

62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 9.4% of Arcutis Biotherapeutics shares are held by insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Arrowhead Pharmaceuticals beats Arcutis Biotherapeutics on 10 of the 17 factors compared between the two stocks.

How does Arcutis Biotherapeutics compare to Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories (NYSE:RDY) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

Dr. Reddy's Laboratories has a beta of 0.25, indicating that its share price is 75% less volatile than the broader market. Comparatively, Arcutis Biotherapeutics has a beta of 1.48, indicating that its share price is 48% more volatile than the broader market.

Arcutis Biotherapeutics has a consensus target price of $34.00, indicating a potential upside of 19.34%. Given Arcutis Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Arcutis Biotherapeutics is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Arcutis Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Dr. Reddy's Laboratories has a net margin of 12.90% compared to Arcutis Biotherapeutics' net margin of -0.57%. Dr. Reddy's Laboratories' return on equity of 12.34% beat Arcutis Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Reddy's Laboratories	12.90%	12.34%	8.24%
Arcutis Biotherapeutics	-0.57%	-1.41%	-0.59%

Dr. Reddy's Laboratories has higher revenue and earnings than Arcutis Biotherapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Reddy's Laboratories	$335.93B	0.03	$456M	$0.58	21.78
Arcutis Biotherapeutics	$415.62M	8.57	-$16.14M	-$0.03	N/A

In the previous week, Dr. Reddy's Laboratories and Dr. Reddy's Laboratories both had 4 articles in the media. Arcutis Biotherapeutics' average media sentiment score of 0.85 beat Dr. Reddy's Laboratories' score of 0.42 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dr. Reddy's Laboratories	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arcutis Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

3.8% of Dr. Reddy's Laboratories shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Dr. Reddy's Laboratories beats Arcutis Biotherapeutics on 8 of the 15 factors compared between the two stocks.

Get Arcutis Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARQT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARQT vs. The Competition

Export

Metric	Arcutis Biotherapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.56B	$3.69B	$6.86B	$12.28B
Dividend Yield	N/A	2.17%	2.67%	9.34%
P/E Ratio	-949.35	21.03	27.21	23.92
Price / Sales	8.57	177.07	517.68	88.89
Price / Cash	N/A	154.08	52.99	60.41
Price / Book	18.38	8.26	10.69	6.18
Net Income	-$16.14M	$23.83M	$3.59B	$332.29M
7 Day Performance	2.70%	-3.47%	-2.20%	-2.05%
1 Month Performance	8.70%	2.69%	1.63%	-2.18%
1 Year Performance	94.21%	45.93%	25.64%	17.67%

Arcutis Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARQT Arcutis Biotherapeutics	3.5426 of 5 stars	$28.49 +2.7%	$34.00 +19.3%	+94.2%	$3.56B	$415.62M	N/A	150
AXSM Axsome Therapeutics	3.6375 of 5 stars	$245.57 -1.7%	$259.05 +5.5%	+105.9%	$12.85B	$638.50M	N/A	380	News Coverage Analyst Forecast
SMMT Summit Therapeutics	3.2677 of 5 stars	$15.69 -1.2%	$26.97 +71.9%	-47.3%	$12.33B	N/A	N/A	110	News Coverage Upcoming Earnings Analyst Forecast Gap Down
ELAN Elanco Animal Health	3.7359 of 5 stars	$24.70 +0.2%	$28.55 +15.6%	+74.8%	$12.31B	$4.72B	N/A	9,400	News Coverage Positive News
ARWR Arrowhead Pharmaceuticals	3.1152 of 5 stars	$85.74 -1.4%	$87.27 +1.8%	+343.3%	$12.25B	$829.45M	N/A	400	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARQT) was last updated on 7/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Arcutis Biotherapeutics (ARQT) Competitors

ARQT vs. AXSM, SMMT, ELAN, ARWR, and RDY

How does Arcutis Biotherapeutics compare to Axsome Therapeutics?

Summary

How does Arcutis Biotherapeutics compare to Summit Therapeutics?

Summary

How does Arcutis Biotherapeutics compare to Elanco Animal Health?

Summary

How does Arcutis Biotherapeutics compare to Arrowhead Pharmaceuticals?

Summary

How does Arcutis Biotherapeutics compare to Dr. Reddy's Laboratories?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARQT vs. The Competition

Arcutis Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Arcutis Biotherapeutics (ARQT) Competitors

ARQT vs. AXSM, SMMT, ELAN, ARWR, and RDY

How does Arcutis Biotherapeutics compare to Axsome Therapeutics?

Do insiders & institutionals have more ownership in ARQT or AXSM?

Which has more risk & volatility, ARQT or AXSM?

Do analysts prefer ARQT or AXSM?

Does the media favor ARQT or AXSM?

Which has higher earnings and valuation, ARQT or AXSM?

Is ARQT or AXSM more profitable?

Summary

How does Arcutis Biotherapeutics compare to Summit Therapeutics?

Does the media refer more to SMMT or ARQT?

Which has more volatility and risk, SMMT or ARQT?

Do analysts recommend SMMT or ARQT?

Which has stronger valuation & earnings, SMMT or ARQT?

Is SMMT or ARQT more profitable?

Do institutionals and insiders have more ownership in SMMT or ARQT?

Summary

How does Arcutis Biotherapeutics compare to Elanco Animal Health?

Which has preferable earnings & valuation, ELAN or ARQT?

Does the media favor ELAN or ARQT?

Do analysts recommend ELAN or ARQT?

Which has more volatility & risk, ELAN or ARQT?

Is ELAN or ARQT more profitable?

Do institutionals and insiders hold more shares of ELAN or ARQT?

Summary

How does Arcutis Biotherapeutics compare to Arrowhead Pharmaceuticals?

Do analysts rate ARQT or ARWR?

Does the media favor ARQT or ARWR?

Which has more volatility & risk, ARQT or ARWR?

Which has preferable valuation and earnings, ARQT or ARWR?

Is ARQT or ARWR more profitable?

Do insiders and institutionals hold more shares of ARQT or ARWR?

Summary

How does Arcutis Biotherapeutics compare to Dr. Reddy's Laboratories?

Which has more volatility & risk, RDY or ARQT?

Do analysts prefer RDY or ARQT?

Is RDY or ARQT more profitable?

Which has higher valuation & earnings, RDY or ARQT?

Does the media refer more to RDY or ARQT?

Do institutionals and insiders have more ownership in RDY or ARQT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARQT vs. The Competition

Arcutis Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools